BIOLARGO, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $516.0K | $281.1K | $127.6K | $111.5K | $167.9K | $65.5K | $156.2K | $156.8K |
| Cost of Revenue | $323.0K | $105.9K | $62.1K | $56.0K | $29.7K | $39.8K | $44.8K | $125.5K |
| Gross Profit | $193.0K | $175.2K | $65.5K | $55.5K | $138.3K | $25.8K | $111.4K | $31.3K |
| Gross Margin | 37.4% | 62.3% | 51.4% | 49.8% | 82.3% | 39.3% | 71.3% | 20.0% |
| Operating Expenses | ||||||||
| Research & Development | $1.6M | $1.4M | $684.6K | $642.9K | $742.2K | $383.5K | $99.5K | $100.6K |
| SG&A Expense | $4.4M | $3.7M | $3.6M | $2.8M | $2.0M | $4.4M | $3.2M | $4.1M |
| Operating Income | $-5.9M | $-4.9M | $-4.2M | $-3.4M | $-2.6M | $-4.7M | $-3.2M | $-4.2M |
| Operating Margin | -1,142.6% | -1,755.5% | -3,277.5% | -3,040.3% | -1,559.8% | -7,197.9% | -2,023.9% | -2,678.3% |
| Interest Expense | $3.9M | $3.1M | $994.7K | $348.2K | $281.6K | $616.4K | $793.3K | $1.7M |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-9.5M | $-8.1M | $-5.1M | $-3.7M | $-2.5M | $-5.3M | $-4.0M | $-5.7M |
| Net Margin | -1,850.2% | -2,872.3% | -3,979.4% | -3,309.9% | -1,505.4% | -8,138.3% | -2,531.8% | -3,663.1% |
| EPS (Basic) | $-0.10 | $-0.09 | $-0.06 | $-0.05 | $-0.04 | $-0.08 | $-0.07 | $-0.13 |
| EPS (Diluted) | $-0.10 | $-0.09 | $-0.06 | $-0.05 | $-0.04 | $-0.08 | $-0.07 | $-0.13 |
| Shares Outstanding (Basic) | 98.9M | 87.9M | 84.1M | 80.0M | 73.0M | 63.8M | 55.7M | 45.8M |
| Shares Outstanding (Diluted) | 98.9M | 87.9M | 84.1M | 80.0M | 73.0M | 63.8M | 55.7M | 45.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |